All Stories

  1. PCSK9 inhibitors and cardiovascular outcomes

    Article • Expert Opinion on Biological Therapy, October 2019, Taylor & Francis

    Peter Bramlage, Professor Ursula Rauch

  2. Impact of Rehabilitation on Outcomes after TAVI: A Preliminary Study

    Article • Journal of Clinical Medicine, October 2018, MDPI AG

    Peter Bramlage

  3. Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, November 2017, Elsevier

    Peter Bramlage

  4. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post...

    Article • International Journal of Cardiology, August 2017, Elsevier

    Peter Bramlage

  5. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease

    Article • European Journal of Heart Failure, June 2017, Wiley

    Peter Bramlage

  6. Cryoballoon vs. open irrigated radiofrequency ablation for paroxysmal atrial fibrillation: long-term FreezeAF outcomes

    Article • BMC Cardiovascular Disorders, May 2017, Springer Science + Business Media

    Peter Bramlage

  7. Blood pressure control and cardiovascular risk in hypertensive patients with type 2 diabetes: The German T2Target registry

    Article • Journal of Clinical Hypertension, May 2017, Wiley

    Peter Bramlage

  8. Erratum to: Validation of the custo screen pediatric blood pressure monitor according to the European Society of Hypertension International Protocol revision 2010

    Article • European Journal of Pediatrics, May 2017, Springer Science + Business Media

    Peter Bramlage

  9. Therapie und Sekundärprävention der venösen Thromboembolie – Orale Antikoagulation im Wandel

    Article • DMW - Deutsche Medizinische Wochenschrift, April 2017, Thieme Publishing Group

    Peter Bramlage

  10. Transaortic transcatheter aortic valve implantation as a first-line choice or as a last resort? An analysis based on the ROUTE registry†

    Article • European Journal of Cardio-Thoracic Surgery, March 2017, Oxford University Press (OUP)

    Peter Bramlage

  11. Management verschiedener kardiovaskulärer Risikofaktoren mit einem Kombinationspräparat („Polypill“)

    Article • Herz, March 2017, Springer Science + Business Media

    Peter Bramlage

  12. Validation of the custo screen pediatric blood pressure monitor according to the European Society of Hypertension International Protocol revision 2010

    Article • European Journal of Pediatrics, February 2017, Springer Science + Business Media

    Peter Bramlage

  13. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation

    Article • Cardiovascular Diabetology, February 2017, Springer Science + Business Media

    Peter Bramlage

  14. Urinary free light chains may help to identify infection in patients with elevated systemic inflammation due to rheumatic disease

    Article • Rheumatology International, February 2017, Springer Science + Business Media

    Peter Bramlage

  15. Management of cardiovascular risk factors in patients with ANCA-associated vasculitis

    Article • Journal of Evaluation in Clinical Practice, February 2017, Wiley

    Peter Bramlage

  16. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk

    Article • European Journal of Preventive Cardiology, February 2017, SAGE Publications

    Peter Bramlage

  17. Response

    Article • Blood Pressure Monitoring, February 2017, Wolters Kluwer Health

    Peter Bramlage

  18. Quality of care assessment and improvement in aortic stenosis - rationale and design of a multicentre registry (IMPULSE)

    Article • BMC Cardiovascular Disorders, January 2017, Springer Science + Business Media

    Peter Bramlage

  19. Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment – A prospective observational study in 2202 patients

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, January 2017, Elsevier

    Peter Bramlage

  20. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients

    Article • Atherosclerosis, December 2016, Elsevier

    Peter Bramlage

  21. Validation of the blood pressure measurement device Erkameter 125 PRO according to the European Society of Hypertension International Protocol revision 2010

    Article • Blood Pressure Monitoring, December 2016, Wolters Kluwer Health

    Peter Bramlage

  22. Betrixaban – the next direct factor Xa inhibitor?

    Article • Expert Review of Hematology, November 2016, Taylor & Francis

    Peter Bramlage

  23. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation

    Article • Expert Review of Clinical Pharmacology, November 2016, Taylor & Francis

    Peter Bramlage

  24. Balloon expandable transcatheter aortic valve implantation via the transfemoral route with or without pre-dilation of the aortic valve – rationale and design of a multicentre registry (EASE-IT TF)

    Article • BMC Cardiovascular Disorders, November 2016, Springer Science + Business Media

    Peter Bramlage

  25. Preprocedural but not periprocedural high-sensitive Troponin T levels predict outcome in patients undergoing transcatheter aortic valve implantation

    Article • Cardiovascular Therapeutics, November 2016, Wiley

    Peter Bramlage

  26. Akute Lungenembolie: immer noch eine diagnostische und therapeutische Herausforderung?

    Article • Medizinische Klinik - Intensivmedizin und Notfallmedizin, November 2016, Springer Science + Business Media

    Peter Bramlage

  27. Quality of life and emotional impact of a fixed-dose combination of antihypertensive drugs in patients with uncontrolled hypertension

    Article • Journal of Clinical Hypertension, October 2016, Wiley

    Peter Bramlage

  28. The significance and predictive value of free light chains in the urine of patients with chronic inflammatory rheumatic disease

    Article • Clinical Rheumatology, October 2016, Springer Science + Business Media

    Peter Bramlage

  29. Endomyocardial biopsy in patients with cardiomyopathy of unknown origin: does specialized center experience apply to a tertiary care hospital?

    Article • BMC Research Notes, October 2016, Springer Science + Business Media

    Peter Bramlage

  30. Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German DIVE and DPV registries

    Article • Diabetes Obesity and Metabolism, September 2016, Wiley

    Peter Bramlage

  31. Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial

    Article • Diabetologia, September 2016, Springer Science + Business Media

    Peter Bramlage

  32. Konsensuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern

    Article • Herzschrittmachertherapie + Elektrophysiologie, August 2016, Springer Science + Business Media

    Christoph Geller, Peter Bramlage

  33. The German Hypertension League (Deutsche Hochdruckliga) Quality Seal Protocol for blood pressure-measuring devices

    Article • Blood Pressure Monitoring, August 2016, Wolters Kluwer Health

    Peter Bramlage

  34. Early improvement of symptoms using LCZ696 in a patient with systolic heart failure and a reduced ejection fraction: a case report

    Article • Perfusion, July 2016, SAGE Publications

    Peter Bramlage

  35. Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategy

    Article • Diabetes Research and Clinical Practice, June 2016, Elsevier

    Peter Bramlage

  36. Non-invasive Renal Denervation: Update on External Ultrasound Approaches

    Article • Current Hypertension Reports, April 2016, Springer Science + Business Media

    Peter Bramlage

  37. Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry

    Article • Journal of Clinical Hypertension, April 2016, Wiley

    Peter Bramlage

  38. Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin

    Article • Acta Diabetologica, April 2016, Springer Science + Business Media

    Peter Bramlage

  39. The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes

    Article • Medicine, April 2016, Wolters Kluwer Health

    Peter Bramlage

  40. Therapie der koronaren Dreigefäßerkrankung bei Patienten über 75 Jahren

    Article • DMW - Deutsche Medizinische Wochenschrift, March 2016, Thieme Publishing Group

    Peter Bramlage

  41. Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry

    Article • BMC Cardiovascular Disorders, March 2016, Springer Science + Business Media

    Peter Bramlage

  42. Is Azilsartan More Effective in Younger Than in Older Patients? An Explorative Analysis of the Prospective EARLY Registry

    Article • Journal of Clinical Hypertension, March 2016, Wiley

    Peter Bramlage

  43. Validation protocols for blood pressure-measuring devices

    Article • Blood Pressure Monitoring, February 2016, Wolters Kluwer Health

    Peter Bramlage

  44. The impact of nutritional status and appetite on the hospital length of stay and postoperative complications in elderly patients with severe aortic stenosis before aortic valve replacement

    Article • Polish Journal of Cardio-Thoracic Surgery, January 2016, Termedia Sp. z.o.o.

    Peter Bramlage

  45. Transaortic transcatheter aortic valve implantation: Results of the Polish arm of the ROUTE registry

    Article • Cardiology Journal, December 2015, VM Media SP. zo.o VM Group SK

    Peter Bramlage

  46. Targeted therapies for treatment of non-small cell lung cancer-Recent advances and future perspectives

    Article • International Journal of Cancer, December 2015, Wiley

    Peter Bramlage

  47. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease

    Article • European Journal of Heart Failure, December 2015, Wiley

    Peter Bramlage

  48. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry

    Article • Trials, December 2015, Springer Science + Business Media

    Peter Bramlage

  49. Incidence, characteristics and impact of hypoglycaemia in patients receiving intensified treatment for inadequately controlled type 2 diabetes mellitus

    Article • Diabetes and Vascular Disease Research, November 2015, SAGE Publications

    Peter Bramlage

  50. Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry

    Article • BMC Endocrine Disorders, October 2015, Springer Science + Business Media

    Peter Bramlage

  51. Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation

    Article • Circulation, October 2015, Wolters Kluwer Health

    Peter Bramlage

  52. Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of DiaRegis cohort

    Article • Acta Diabetologica, August 2015, Springer Science + Business Media

    Peter Bramlage

  53. Elevated growth differentiation factor 15 levels predict outcome in patients undergoing transcatheter aortic valve implantation

    Article • European Journal of Heart Failure, July 2015, Wiley

    Peter Bramlage

  54. Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry

    Article • Journal of Clinical Hypertension, June 2015, Wiley

    Peter Bramlage

  55. Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives

    Article • Cancer Chemotherapy and Pharmacology, May 2015, Springer Science + Business Media

    Peter Bramlage

  56. Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry

    Article • BMC Endocrine Disorders, May 2015, Springer Science + Business Media

    Peter Bramlage

  57. Prinzmetal-Angina nach Lakritz-Konsum

    Article • DMW - Deutsche Medizinische Wochenschrift, April 2015, Thieme Publishing Group

    Peter Bramlage

  58. A comparison of transcatheter aortic valve implantation and surgical aortic valve replacement in 1,141 patients with severe symptomatic aortic stenosis and less than high risk

    Article • Catheterization and Cardiovascular Interventions, March 2015, Wiley

    Peter Bramlage

  59. Treatment of Heart Failure in Real-World Clinical Practice: Findings From the REFLECT-HF Registry in Patients With NYHA Class II Symptoms and a Reduced Ejection Fraction

    Article • Clinical Cardiology, March 2015, Wiley

    Peter Bramlage

  60. LCZ696: a new paradigm for the treatment of heart failure?

    Article • Expert Opinion on Pharmacotherapy, January 2015, Informa Healthcare

    Peter Bramlage

  61. A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy

    Article • Cardiovascular Diabetology, January 2015, Springer Science + Business Media

    Peter Bramlage

  62. Chronic Obstructive Pulmonary Disease and Diabetes Mellitus: A Systematic Review of the Literature

    Article • Respiration, January 2015, Karger Publishers

    Peter Bramlage

  63. Current Perspectives on the Contribution of Inhaled Corticosteroids to an Increased Risk for Diabetes Onset and Progression in Patients with Chronic Obstructive Pulmonary Disease

    Article • Respiration, January 2015, Karger Publishers

    Peter Bramlage

  64. Long-Term Results of Transapical Versus Transfemoral TAVI in a Real World Population of 1000 Patients With Severe Symptomatic Aortic Stenosis

    Article • Circulation Cardiovascular Interventions, January 2015, Wolters Kluwer Health

    Peter Bramlage

  65. Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice

    Article • Vascular Health and Risk Management, December 2014, Taylor & Francis

    Peter Bramlage

  66. Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up

    Article • BMC Cardiovascular Disorders, November 2014, Springer Science + Business Media

    Peter Bramlage

  67. Clinical impact of a new left bundle branch block following TAVI implantation: 1-year results of the TAVIK cohort

    Article • Clinical Research in Cardiology, November 2014, Springer Science + Business Media

    Peter Bramlage

  68. Transaortic transcatheter aortic valve implantation - rationale and design of the multicenter, multinational prospective ROUTE registry

    Article • BMC Cardiovascular Disorders, November 2014, Springer Science + Business Media

    Peter Bramlage

  69. U300, a novel long-acting insulin formulation

    Article • Expert Opinion on Biological Therapy, October 2014, Informa Healthcare

    Peter Bramlage

  70. The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry

    Article • Journal of Human Hypertension, October 2014, Springer Science + Business Media

    Peter Bramlage

  71. Comparison of the Omron RS6 wrist blood pressure monitor with the positioning sensor on or off with a standard mercury sphygmomanometer

    Article • Blood Pressure Monitoring, October 2014, Wolters Kluwer Health

    Peter Bramlage

  72. Continuation of venous thromboembolism prophylaxis after hospital discharge into the outpatient setting: the ACCEPT study

    Article • Journal of Thrombosis and Thrombolysis, July 2014, Springer Science + Business Media

    Peter Bramlage

  73. Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients

    Article • BMC Research Notes, July 2014, Springer Science + Business Media

    Peter Bramlage

  74. Clinical significance of conduction disturbances after aortic valve intervention: current evidence

    Article • Clinical Research in Cardiology, July 2014, Springer Science + Business Media

    Peter Bramlage

  75. Ruptures of the device landing zone in patients undergoing transcatheter aortic valve implantation: an analysis of TAVI Karlsruhe (TAVIK) patients

    Article • Clinical Research in Cardiology, June 2014, Springer Science + Business Media

    Peter Bramlage

  76. Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin

    Article • Expert Opinion on Pharmacotherapy, May 2014, Informa Healthcare

    Peter Bramlage

  77. Perioperatives Gerinnungsmanagement bei oraler Antikoagulation

    Article • Der Chirurg, May 2014, Springer Science + Business Media

    Peter Bramlage

  78. Validation of the custo screen 400 ambulatory blood pressure-monitoring device according to the European Society of Hypertension International Protocol revision 2010

    Article • Vascular Health and Risk Management, May 2014, Taylor & Francis

    Peter Bramlage

  79. Clinical Impact of Patient Adherence to a Fixed-Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide

    Article • Clinical Drug Investigation, April 2014, Springer Science + Business Media

    Peter Bramlage

  80. Predictors of Response to Early Basal Insulin Treatment in Patients with Type 2 Diabetes—The EARLY Experience

    Article • Diabetes Technology & Therapeutics, April 2014, Mary Ann Liebert Inc

    Peter Bramlage

  81. Prevalence and control of high blood pressure in primary care-results from the German metabolic and cardiovascular risk study (GEMCAS)

    Article • Hypertension Research, March 2014, Springer Science + Business Media

    Peter Bramlage

  82. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF

    Article • Clinical Research in Cardiology, February 2014, Springer Science + Business Media

    Peter Bramlage

  83. Comprehensive geriatric assessment in patients undergoing transcatheter aortic valve implantation–rationale and design of the European CGA-TAVI registry

    Article • European Geriatric Medicine, February 2014, Elsevier

    Peter Bramlage

  84. Candesartan Cilexetil 32 mg/Hydrochlorothiazide 25 mg in Unselected Patients with High or Very High Cardiovascular Risk: Efficacy, Safety, and Metabolic Impact

    Article • Clinical Drug Investigation, January 2014, Springer Science + Business Media

    Peter Bramlage

  85. Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical Perspective on the Prevalence and Characteristics of Lipid Abnormalities in the Setting of Chronic Statin Treatment

    Article • PLoS ONE, January 2014, PLOS

    Dr Saud Nafa Al Sifri, Peter Bramlage

  86. Effects of 8,000 IU aXa long-term prophylaxis with certoparin on the incidence of hyperkalemia in patients with coronary heart disease – a post-hoc analysis of the PARAT trial

    Article • BMC Research Notes, January 2014, Springer Science + Business Media

    Peter Bramlage

  87. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes

    Article • Cardiovascular Diabetology, January 2014, Springer Science + Business Media

    Peter Bramlage

  88. Prevalence of dyslipidemia in statin-treated patients in the Baltic states (Estonia, Latvia, and Lithuania): Results of the Dyslipidemia International Study (DYSIS)

    Article • Medicina, January 2014, MDPI AG

    Peter Bramlage

  89. Transapical Angiography in a Patient With Severe Aortic Stenosis Undergoing Transapical Transcatheter Aortic Valve Implantation

    Article • The Annals of Thoracic Surgery, December 2013, Elsevier

    Peter Bramlage

  90. Daytime Systolic Ambulatory Blood Pressure With a Two-Step Switch From Candesartan to Olmesartan Monotherapy and the Fixed-Dose Combination of Olmesartan/Amlodipine in Patients With Uncontrolled Essential Hypertension (SEVICONTROL-2)

    Article • Journal of Clinical Hypertension, November 2013, Wiley

    Peter Bramlage

  91. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study

    Article • Vascular Health and Risk Management, November 2013, Taylor & Francis

    Peter Bramlage

  92. Prevalence of dyslipidaemia in statin-treated patients in South Africa : results of the DYSlipidaemia International Study (DYSIS)

    Article • CardioVascular Journal of Africa, October 2013, Clinics Cardive Publishing

    Peter Bramlage

  93. Stellenwert der Lyse im Rettungswesen

    Article • Notfall + Rettungsmedizin, October 2013, Springer Science + Business Media

    Peter Bramlage

  94. Percentile distribution of blood pressure readings in 35683 men and women aged 18 to 99 years

    Article • Journal of Human Hypertension, September 2013, Springer Science + Business Media

    Peter Bramlage

  95. Composite efficacy parameters and predictors of hypoglycaemia in basal-plus insulin therapy-a combined analysis of 713 type 2 diabetic patients

    Article • Diabetes Obesity and Metabolism, September 2013, Wiley

    Peter Bramlage

  96. Daytime Systolic Ambulatory Blood Pressure With a Direct Switch Between Candesartan Monotherapy and the Fixed-Dose Combination Olmesartan/Amlodipine in Patients With Uncontrolled Essential Hypertension (SEVICONTROL-1)

    Article • Journal of Clinical Hypertension, September 2013, Wiley

    Peter Bramlage

  97. The DYSlipidemia International Study (DYSIS)-Egypt: A report on the prevalence of lipid abnormalities in Egyptian patients on chronic statin treatment

    Article • The Egyptian Heart Journal, September 2013, Springer Science + Business Media

    Peter Bramlage

  98. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry

    Article • International Journal of Clinical Practice, August 2013, Wiley

    Peter Bramlage

  99. Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice

    Article • Vascular Health and Risk Management, August 2013, Taylor & Francis

    Peter Bramlage

  100. EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry

    Article • BMC Cardiovascular Disorders, July 2013, Springer Science + Business Media

    Peter Bramlage

  101. A call to action - Geriatricians’ experience in treatment of aortic stenosis and involvement in transcatheter aortic valve implantation

    Article • European Geriatric Medicine, June 2013, Elsevier

    Peter Bramlage

  102. DIabetes Versorgungs-Evaluation (DIVE) - eine nationale Initiative zur Qualitätssicherung in der diabetologischen Versorgung

    Article • DMW - Deutsche Medizinische Wochenschrift, April 2013, Thieme Publishing Group

    Peter Bramlage

  103. Abschätzung des kardiovaskulären Risikos

    Article • Der Nephrologe, February 2013, Springer Science + Business Media

    Peter Bramlage

  104. Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial

    Article • Current Diabetes Reports, February 2013, Springer Science + Business Media

    Peter Bramlage

  105. Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents

    Article • Clinical Research in Cardiology, January 2013, Springer Science + Business Media

    Peter Bramlage

  106. Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review

    Article • Cardiovascular Diabetology, January 2013, Springer Science + Business Media

    Peter Bramlage

  107. Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy – an analysis of the DiaRegis registry

    Article • Cardiovascular Diabetology, January 2013, Springer Science + Business Media

    Peter Bramlage

  108. The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes

    Article • Cardiovascular Diabetology, January 2013, Springer Science + Business Media

    Peter Bramlage

  109. Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?

    Article • European Journal of Heart Failure, December 2012, Wiley

    Peter Bramlage

  110. Validation of the Beurer BM 44 upper arm blood pressure monitor for home measurement, according to the European Society of Hypertension International Protocol 2002

    Article • Blood Pressure Monitoring, December 2012, Wolters Kluwer Health

    Peter Bramlage

  111. Diagnostik, Bedeutung, Prävention und Therapie einer Mikroalbuminurie - Erwiderung

    Article • DMW - Deutsche Medizinische Wochenschrift, November 2012, Thieme Publishing Group

    Peter Bramlage

  112. Bridging with the Low molecular weight heparin certoparin in patients requiring temporary discontinuation of oral anticoagulation – the non-interventional, retrospective REMEMBER study

    Article • Thrombosis Research, November 2012, Elsevier

    Peter Bramlage

  113. Incidence and predictors of hypoglycaemia in type 2 diabetes – an analysis of the prospective DiaRegis registry

    Article • BMC Endocrine Disorders, October 2012, Springer Science + Business Media

    Peter Bramlage

  114. Benefits and Risks of Preventing Thromboembolism With Enoxaparin in Patients With General Surgery in Real World—The CLEVER Study

    Article • Clinical and Applied Thrombosis/Hemostasis, October 2012, SAGE Publications

    Peter Bramlage

  115. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia

    Article • European Journal of Clinical Pharmacology, October 2012, Springer Science + Business Media

    Peter Bramlage

  116. Microalbuminuria indicates long-term vascular risk in patients after acute stroke undergoing in-patient rehabilitation

    Article • BMC Neurology, September 2012, Springer Science + Business Media

    Peter Bramlage

  117. Diabetes prevalence and metabolic risk profile in an unselected population visiting pharmacies in Switzerland

    Article • Vascular Health and Risk Management, September 2012, Taylor & Francis

    Peter Bramlage

  118. A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis – the membrane study

    Article • BMC Nephrology, June 2012, Springer Science + Business Media

    Job Harenberg, Peter Bramlage

  119. Diagnostik, Bedeutung, Prävention und Therapie einer Mikroalbuminurie

    Article • DMW - Deutsche Medizinische Wochenschrift, June 2012, Thieme Publishing Group

    Peter Bramlage

  120. Prospective, Non-interventional Study on the Real-World Use of Certoparin in Daily Practice—The PROMEMBER Study

    Article • Clinical and Applied Thrombosis/Hemostasis, June 2012, SAGE Publications

    Peter Bramlage

  121. Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs

    Article • British Journal of Pharmacology, May 2012, Wiley

    Peter Bramlage

  122. Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension

    Article • Clinical Research in Cardiology, April 2012, Springer Science + Business Media

    Dr Felix Mahfoud, Peter Bramlage, Massimo Volpe

  123. Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany

    Article • Herz, April 2012, Springer Science + Business Media

    Peter Bramlage

  124. Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study

    Article • Vascular Health and Risk Management, March 2012, Taylor & Francis

    Peter Bramlage

  125. Health related quality of life in patients with critical limb ischemia

    Article • VASA, March 2012, Hogrefe Publishing Group

    Peter Bramlage

  126. Vascular Risk Prediction in Ischemic Stroke Patients Undergoing in-patient Rehabilitation – Insights from the Investigation of Patients with Ischemic Stroke in Neurologic Rehabilitation (INSIGHT) Registry

    Article • International Journal of Stroke, February 2012, SAGE Publications

    Peter Bramlage

  127. Chronobiologie des Blutdrucks und Chronopharmakotherapie der arteriellen Hypertonie

    Article • DMW - Deutsche Medizinische Wochenschrift, February 2012, Thieme Publishing Group

    Peter Bramlage

  128. Treatment of hypertension in the elderly: data from an international cohort of hypertensives treated by cardiologists

    Article • Journal of Human Hypertension, January 2012, Springer Science + Business Media

    Peter Bramlage

  129. Comparison of 3,000 and 5,000 IU aXa/day certoparin in the prevention of deep-vein thrombosis after total hip replacement

    Article • Thrombosis Journal, January 2012, Springer Science + Business Media

    Peter Bramlage

  130. Hypertension Control and Cardiometabolic Risk: A Regional Perspective

    Article • Cardiology Research and Practice, January 2012, Hindawi Publishing Corporation

    Peter Bramlage, Massimo Volpe

  131. Improved survival of patients with coronary artery disease and low ejection fraction with ICD implantation versus conventional therapy in a real world survey

    Article • BMC Research Notes, January 2012, Springer Science + Business Media

    Peter Bramlage

  132. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia

    Article • Cardiovascular Diabetology, January 2012, Springer Science + Business Media

    Peter Bramlage

  133. Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study

    Article • Cardiovascular Diabetology, January 2012, Springer Science + Business Media

    Peter Bramlage

  134. Concurrent drug eluting/bare metal stent implantation during percutaneous coronary intervention in target vessel: outcomes and 1-year follow-up

    Article • Clinical Research in Cardiology, December 2011, Springer Science + Business Media

    Peter Bramlage

  135. Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU Soon

    Article • Vascular Health and Risk Management, December 2011, Taylor & Francis

    Peter Bramlage

  136. Prevention of Venous Thromboembolism Using Enoxaparin in Day Surgery

    Article • Clinical and Applied Thrombosis/Hemostasis, November 2011, SAGE Publications

    Peter Bramlage

  137. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: An analysis of the CERTIFY study

    Article • Thrombosis Research, November 2011, Elsevier

    Peter Bramlage

  138. Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure

    Article • Expert Opinion on Pharmacotherapy, October 2011, Informa Healthcare

    Peter Bramlage

  139. Prophylaxe thromboembolischer Ereignisse in der Chirurgie

    Article • Der Unfallchirurg, September 2011, Springer Science + Business Media

    Peter Bramlage

  140. Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents

    Article • Clinical Research in Cardiology, September 2011, Springer Science + Business Media

    Peter Bramlage

  141. Physical activity is inversely associated with microalbuminuria in hypertensive patients at high cardiovascular risk: data from I-SEARCH

    Article • European Journal of Preventive Cardiology, September 2011, SAGE Publications

    Peter Bramlage, Massimo Volpe

  142. Biomarkers: optimizing treatment guidance in heart failure

    Article • Clinical Research in Cardiology, July 2011, Springer Science + Business Media

    Peter Bramlage

  143. Cerebral Microangiopathy in Treatment-Resistant Hypertension

    Article • Journal of Clinical Hypertension, July 2011, Wiley

    Peter Bramlage

  144. Clinical efficacy of aldosterone-blocking agents

    Article • European Heart Journal Supplements, June 2011, Oxford University Press (OUP)

    Peter Bramlage

  145. Role of biomarkers in guiding treatment with aldosterone-blocking agents

    Article • European Heart Journal Supplements, June 2011, Oxford University Press (OUP)

    Peter Bramlage

  146. Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: an analysis of the DiaRegis registry

    Article • European Journal of Preventive Cardiology, May 2011, SAGE Publications

    Peter Bramlage

  147. Standards for subgroup analyses are needed?—we couldn’t agree more

    Article • Journal of Clinical Epidemiology, April 2011, Elsevier

    Peter Bramlage

  148. Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)

    Article • Vascular Health and Risk Management, February 2011, Taylor & Francis

    Peter Bramlage

  149. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: A subgroup analysis of the randomized, controlled CERTIFY study

    Article • American Heart Journal, February 2011, Elsevier

    Peter Bramlage

  150. Treatment of peripheral arterial disease using stem and progenitor cell therapy

    Article • Journal of Vascular Surgery, February 2011, Elsevier

    Peter Bramlage

  151. Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists

    Article • Clinical Research in Cardiology, January 2011, Springer Science + Business Media

    Peter Bramlage

  152. CERTIFY: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency

    Article • Thrombosis and Haemostasis, January 2011, Thieme Publishing Group

    Peter Bramlage

  153. Nierenarterienstenose: Intervention oder medikamentöse Behandlung?

    Article • DMW - Deutsche Medizinische Wochenschrift, January 2011, Thieme Publishing Group

    Peter Bramlage

  154. Venous thromboembolism in medical outpatients – a cross-sectional survey of risk assessment and prophylaxis

    Article • Thrombosis and Haemostasis, January 2011, Thieme Publishing Group

    Peter Bramlage

  155. Improvement of Coronary Microvascular Function After Angiotensin Receptor Blocker Treatment With Irbesartan in Patients With Systemic Hypertension

    Article • Journal of Clinical Hypertension, December 2010, Wiley

    Peter Bramlage

  156. Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed

    Article • Journal of Clinical Epidemiology, December 2010, Elsevier

    Peter Bramlage

  157. Bone Morphogenetic Protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis

    Article • BMC Nephrology, November 2010, Springer Science + Business Media

    Peter Bramlage

  158. Going beyond the optimization of pharmacotherapy

    Article • Hypertension Research, November 2010, Springer Science + Business Media

    Peter Bramlage

  159. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN

    Article • Expert Opinion on Pharmacotherapy, October 2010, Informa Healthcare

    Peter Bramlage

  160. Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care

    Article • Expert Opinion on Pharmacotherapy, October 2010, Informa Healthcare

    Peter Bramlage

  161. Follow-Up of Cardiovascular Risk Markers in Hypertensive Patients Treated With Irbesartan: Results of the i-SEARCH Plus Registry

    Article • Journal of Clinical Hypertension, August 2010, Wiley

    Peter Bramlage

  162. Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice

    Article • Vascular Health and Risk Management, August 2010, Taylor & Francis

    Peter Bramlage

  163. Pharmaka zur Thrombozyten- und Gerinnungshemmung in der Behandlung des akuten Koronarsyndroms

    Article • Der Kardiologe, May 2010, Springer Science + Business Media

    Peter Bramlage

  164. A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients

    Article • Journal of Clinical Hypertension, May 2010, Wiley

    Peter Bramlage, Massimo Volpe

  165. Candesartan Cilexetil/Hydrochlorothiazide Treatment in High-Risk Patients with Type 2 Diabetes Mellitus and Microalbuminuria

    Article • Clinical Drug Investigation, May 2010, Springer Science + Business Media

    Peter Bramlage

  166. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction

    Article • Heart, March 2010, BMJ

    Peter Bramlage

  167. Persistence with asthma treatment is low in Germany especially for controller medication - a population based study of 483 051 patients

    Article • Allergy, March 2010, Wiley

    Peter Bramlage

  168. Cost-effectiveness of the artificial liver support system MARS in patients with acute-on-chronic liver failure

    Article • European Journal of Gastroenterology & Hepatology, February 2010, Wolters Kluwer Health

    Peter Bramlage

  169. Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional study

    Article • Cardiovascular Diabetology, January 2010, Springer Science + Business Media

    Peter Bramlage

  170. Concurrent Chemoradiation Therapy With Docetaxel/Cisplatin Followed by Docetaxel Consolidation Therapy in Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer: Results of a Phase I Study

    Article • Clinical Lung Cancer, January 2010, Elsevier

    Peter Bramlage

  171. Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline

    Article • Cardiovascular Diabetology, January 2010, Springer Science + Business Media

    Peter Bramlage

  172. Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension

    Article • Drugs of Today, January 2010, Prous Science

    Peter Bramlage

  173. Stem cell and progenitor cell therapy in peripheral artery disease

    Article • Thrombosis and Haemostasis, January 2010, Thieme Publishing Group

    Peter Bramlage

  174. Differences in pharmacology and their translation into differences in clinical efficacy – a comparison of the renin angiotensin blocking agents irbesartan and losartan

    Article • Expert Opinion on Pharmacotherapy, December 2009, Informa Healthcare

    Peter Bramlage

  175. Nitric oxide and endothelin after lipid apheresis – a pilot study

    Article • Atherosclerosis Supplements, December 2009, Elsevier

    Peter Bramlage

  176. Long-term outcomes after medical and interventional therapy of critical limb ischemia

    Article • European Journal of Internal Medicine, October 2009, Elsevier

    Peter Bramlage

  177. Qualität der fachärztlichen Hypertoniebehandlung – Daten aus einer internationalen Querschnittsuntersuchung

    Article • Gesundheitsökonomie & Qualitätsmanagement, October 2009, Thieme Publishing Group

    Peter Bramlage

  178. Thromboembolierisiko und -prophylaxe internistischer und chirurgischer Patienten im Krankenhaus

    Article • DMW - Deutsche Medizinische Wochenschrift, October 2009, Thieme Publishing Group

    Peter Bramlage

  179. Angiotensin Blockade to Reduce Microvascular Damage in Diabetes Mellitus

    Article • Deutsches Ärzteblatt international, August 2009, Deutscher Arzte-Verlag GmbH

    Peter Bramlage

  180. In-hospital outcomes after elective and non-elective percutaneous coronary interventions in hospitals with and without on-site cardiac surgery backup

    Article • Clinical Research in Cardiology, July 2009, Springer Science + Business Media

    Peter Bramlage

  181. The value of irbesartan in the management of hypertension

    Article • Expert Opinion on Pharmacotherapy, July 2009, Informa Healthcare

    Peter Bramlage

  182. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension

    Article • Expert Opinion on Pharmacotherapy, June 2009, Informa Healthcare

    Peter Bramlage

  183. Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients

    Article • European Heart Journal, April 2009, European Society of Cardiology

    Peter Bramlage, Massimo Volpe

  184. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles

    Article • European Heart Journal, March 2009, European Society of Cardiology

    Peter Bramlage

  185. Angiotensin-Rezeptorblocker - Welche Bedeutung haben Unterschiede in der Pharmakologie für die Wirksamkeit in der Klinik?

    Article • Notfall & Hausarztmedizin, February 2009, Thieme Publishing Group

    Peter Bramlage

  186. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review

    Article • Cardiovascular Diabetology, January 2009, Springer Science + Business Media

    Peter Bramlage

  187. Desmoteplase in acute massive pulmonary thromboembolism

    Article • Thrombosis and Haemostasis, January 2009, Thieme Publishing Group

    Peter Bramlage

  188. Ambulante Behandlung tiefer Beinvenenthrombosen mit Enoxaparin

    Article • Medizinische Klinik, January 2009, Springer Science + Business Media

    Peter Bramlage

  189. Predictors of complications in therapeutic plasma exchange

    Article • Journal of Clinical Apheresis, January 2009, Wiley

    Peter Bramlage

  190. Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy)

    Article • BMC Cancer, December 2008, Springer Science + Business Media

    Peter Bramlage

  191. Overweight, Obesity and High Waist Circumference – Regional Differences in Prevalence in Primary Medical Care

    Article • Deutsches Ärzteblatt international, November 2008, Deutscher Arzte-Verlag GmbH

    Peter Bramlage

  192. Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care

    Article • BMC Cardiovascular Disorders, November 2008, Springer Science + Business Media

    Peter Bramlage

  193. Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers

    Article • BMC Pharmacology, October 2008, Springer Science + Business Media

    Peter Bramlage

  194. Regional Differences in the Prevalence of the Metabolic Syndrome in Primary Care - Practices in Germany: In Reply

    Article • Deutsches Ärzteblatt international, October 2008, Deutscher Arzte-Verlag GmbH

    Peter Bramlage

  195. Prevalence of obesity in primary care using different anthropometric measures – Results of the German Metabolic and Cardiovascular Risk Project (GEMCAS)

    Article • BMC Public Health, August 2008, Springer Science + Business Media

    Peter Bramlage

  196. The correlation between waist circumference and ESC cardiovascular risk score: data from the German metabolic and cardiovascular risk project (GEMCAS)

    Article • Clinical Research in Cardiology, July 2008, Springer Science + Business Media

    Peter Bramlage

  197. Epidemiologie und Komorbiditäten der Adipositas in Deutschland

    Article • Der Diabetologe, April 2008, Springer Science + Business Media

    Peter Bramlage

  198. Regional Differences in the Prevalence of the Metabolic Syndrome in Primary Care Practices in Germany

    Article • Deutsches Ärzteblatt international, March 2008, Deutscher Arzte-Verlag GmbH

    Peter Bramlage

  199. Defined Daily Doses: Ein Instrument zur Kostensteuerung im Gesundheitswesen?

    Article • Gesundheitsökonomie & Qualitätsmanagement, February 2008, Thieme Publishing Group

    Peter Bramlage

  200. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH

    Article • Journal of Hypertension, January 2008, Wolters Kluwer Health

    Peter Bramlage, Massimo Volpe

  201. Dyslipidemia in primary care – prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)

    Article • Cardiovascular Diabetology, January 2008, Springer Science + Business Media

    Peter Bramlage

  202. First-line antihypertensive treatment in patients with pre-diabetes: Rationale, design and baseline results of the ADaPT investigation

    Article • Cardiovascular Diabetology, January 2008, Springer Science + Business Media

    Peter Bramlage

  203. Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration

    Article • Thrombosis and Haemostasis, January 2008, Thieme Publishing Group

    Peter Bramlage

  204. Modulatory effects of inflammation and therapy on GDF‐5 expression in rheumatoid arthritis synovium

    Article • Scandinavian Journal of Rheumatology, January 2008, Taylor & Francis

    Peter Bramlage

  205. Comparison of Selective AT1-Receptor Blockade Versus ACE Inhibition for Restenosis Prophylaxis in Patients With Peripheral Occlusive Arterial Disease After Stent Angioplasty: A Randomized, Controlled, Proof-of-Concept Study

    Article • Angiology, November 2007, SAGE Publications

    Peter Bramlage

  206. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study

    Article • Journal of Hypertension, November 2007, Wolters Kluwer Health

    Peter Bramlage, Massimo Volpe

  207. Aktuelle Beispiele für Arzneimittel (-entwicklungen) in der primären, sekundären und tertiären Prävention

    Article • DMW - Deutsche Medizinische Wochenschrift, October 2007, Thieme Publishing Group

    Peter Bramlage

  208. Prevalence of Undiagnosed Type-2-Diabetes Mellitus and Impaired Fasting Glucose in German Primary Care: Data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)

    Article • Experimental and Clinical Endocrinology & Diabetes, October 2007, Thieme Publishing Group

    Peter Bramlage

  209. Langzeitverlauf kardiovaskulärer Risikomarker bei Patienten mit Hypertonie

    Article • Medizinische Klinik, October 2007, Springer Science + Business Media

    Peter Bramlage

  210. Prävention kardiovaskulärer Erkrankungen durch Blockade des Endocannabinoidsystems

    Article • Herz, October 2007, Springer Science + Business Media

    Peter Bramlage

  211. Behandlung des akuten Koronarsyndroms in Deutschland: Erfahrungen eines deutschen Clusters des GRACE-Registers

    Article • DMW - Deutsche Medizinische Wochenschrift, September 2007, Thieme Publishing Group

    Peter Bramlage

  212. Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease

    Article • Future Cardiology, September 2007, Future Medicine

    Peter Bramlage

  213. Niedermolekulare Heparine zur Thromboseprophylaxe nach ischämischem Schlaganfall

    Article • Aktuelle Neurologie, September 2007, Thieme Publishing Group

    Peter Bramlage

  214. Rückgang der Krankenhaus-Sterblichkeit und verbesserte Sekundärprävention nach akutem Myokardinfarkt

    Article • DMW - Deutsche Medizinische Wochenschrift, July 2007, Thieme Publishing Group

    Peter Bramlage

  215. Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats

    Article • European Journal of Pharmacology, June 2007, Elsevier

    Peter Bramlage

  216. Low-grade albuminuria and cardiovascular risk

    Article • Clinical Research in Cardiology, April 2007, Springer Science + Business Media

    Peter Bramlage

  217. Clinical practice and recent recommendations in hypertension management – reporting a gap in a global survey of 1259 primary care physicians in 17 countries

    Article • Current Medical Research and Opinion, March 2007, Informa Healthcare

    Peter Bramlage

  218. Frequency of albuminuria in primary care: a cross-sectional study

    Article • European Journal of Cardiovascular Prevention & Rehabilitation, February 2007, SAGE Publications

    Peter Bramlage

  219. Comparison of Inhibitory Effects of Irbesartan and Atorvastatin Treatment on the Renin Angiotensin System (RAS) in Veins: A Randomized Double-Blind Crossover Trial in Healthy Subjects

    Article • The Journal of Clinical Pharmacology, January 2007, Wiley

    Peter Bramlage

  220. Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare:The German Metabolic and Cardiovascular Risk Project (GEMCAS)

    Article • Cardiovascular Diabetology, January 2007, Springer Science + Business Media

    Peter Bramlage

  221. Prevalence of deep vein thrombosis (DVT) in non-surgical patients at hospital admission

    Article • Thrombosis and Haemostasis, January 2007, Thieme Publishing Group

    Peter Bramlage

  222. Subklinische Albuminurie, Mikroalbuminurie und Proteinurie - akzeptierte kardiovaskuläre Risikomarker?

    Article • DMW - Deutsche Medizinische Wochenschrift, November 2006, Thieme Publishing Group

    Peter Bramlage

  223. Klinische Pharmakologie: Erkenntnisgewinn zu Arzneimitteln nach der Zulassung

    Article • DMW - Deutsche Medizinische Wochenschrift, June 2006, Thieme Publishing Group

    Peter Bramlage

  224. Pharmakoepidemiologie antihypertensiver Medikamente bei adipösen Patienten

    Article • Medizinische Klinik, December 2005, Springer Science + Business Media

    Peter Bramlage

  225. Bone Morphogenetic Proteins im Skelettsystem—

    Article • Zeitschrift für Rheumatologie, September 2005, Springer Science + Business Media

    Peter Bramlage

  226. Effect of three months’ treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31 793 patients

    Article • Current Medical Research and Opinion, August 2005, Informa Healthcare

    Peter Bramlage

  227. Transforming growth factor-β1 downregulates beating frequency and remodeling of cultured rat adult cardiomyocytes

    Article • Cell and Tissue Research, May 2005, Springer Science + Business Media

    Peter Bramlage

  228. Innovation not imitation - news in drug therapy

    Article • DMW - Deutsche Medizinische Wochenschrift, April 2005, Thieme Publishing Group

    Peter Bramlage

  229. Die Blockade des Endocannabinoidsystems - Gewichtsreduktion und kardiovaskuläres Risikomanagement

    Article • DMW - Deutsche Medizinische Wochenschrift, March 2005, Thieme Publishing Group

    Peter Bramlage

  230. Antihypertensive Effect of Irbesartan and Predictors of Response in Obesity-Associated Hypertension

    Article • Clinical Drug Investigation, January 2005, Springer Science + Business Media

    Peter Bramlage

  231. Drug interactions with angiotensin receptor blockers

    Article • Expert Opinion on Drug Safety, January 2005, Informa Healthcare

    Peter Bramlage

  232. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled

    Article • American Journal of Hypertension, October 2004, Oxford University Press (OUP)

    Peter Bramlage

  233. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care

    Article • Current Medical Research and Opinion, September 2004, Informa Healthcare

    Peter Bramlage

  234. Arzneimittelinteraktionen im Alter

    Article • DMW - Deutsche Medizinische Wochenschrift, April 2004, Thieme Publishing Group

    Peter Bramlage

  235. Patterns of antihypertensive drug utilization in primary care

    Article • European Journal of Clinical Pharmacology, April 2004, Springer Science + Business Media

    Peter Bramlage

  236. Regression of Microalbuminuria in???Type 2 Diabetics after Switch to???Irbesartan Treatment

    Article • Clinical Drug Investigation, January 2004, Springer Science + Business Media

    Peter Bramlage

  237. Pattern of prescriptions issued by nursing home-based physicians versus office-based physicians for frail elderly patients in German nursing homes

    Article • Pharmacoepidemiology and Drug Safety, January 2003, Wiley

    Peter Bramlage

  238. Cardiac troponin I sense-antisense RNA duplexes in the myocardium

    Article • Journal of Cellular Biochemistry, January 2002, Wiley

    Peter Bramlage

  239. Computer-Aided Measurement of Cell Shortening and Calcium Transients in Adult Cardiac Myocytes

    Article • Biotechnology Progress, October 2001, Wiley

    Peter Bramlage

  240. Soluble substances released from postischemic reperfused rat hearts reduce calcium transient and contractility by blocking the l-type calcium channel

    Article • Journal of the American College of Cardiology, February 2001, Elsevier

    Peter Bramlage

  241. Adrenomedullin and myocardial contractility in the rat

    Article • European Journal of Pharmacology, November 2000, Elsevier

    Peter Bramlage